Gain of CBL-interacting protein, a possible alternative to CBL mutations in myeloid malignancies

Leukemia

Volumn 24, Issue 8, 2010, Pages 1539-1541

  Adelade J ^a   Gelsi Boyer, V ^a,b,c   Rocquain, J ^a   Carbuccia, N ^a   Birnbaum, D J ^a   Finetti, P ^a   Bertucci, F ^a,c   Mozziconacci, M J ^a,b   Vey, N ^b,c   Birnbaum, D ^a   Chaffanet, M ^a  

^a INSERM   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CBL PROTEIN; SH3 DOMAIN KINASE BINDING PROTEIN 1; UNCLASSIFIED DRUG;

CBL GENE; CHROMOSOME 11Q; CHRONIC MYELOMONOCYTIC LEUKEMIA; COMPARATIVE GENOMIC HYBRIDIZATION; DNA SEQUENCE; GENE; GENE DUPLICATION; GENE MUTATION; GENOME; HOMOZYGOSITY; HUMAN; LETTER; LEUKOCYTOSIS; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; PROTEIN INTERACTION; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; SIGNAL TRANSDUCTION;

EID: 77955717878     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.135     Document Type: Letter

References (14)

1. Dunbar AJ, Gondek LP, O'Keefe CL, Makishima H, Rataul MS, Szpurka H et al. 250K single nucleotide polymorphism arraykaryotyping identifies acquired uniparental disomy and homo-zygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res 2008; 68: 10340-10357.
2. Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009; 113: 6182-6192.
3. Makishima H, Cazzolli H, Szpurka H, Dunbar A, Tiu R, Huh J et al. Mutations of E3 ligase Cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol 2009; 27: 6109-6116.
4. Sanada M, Suzuki T, Shih LY, Otsu M, Kato M, Yamasaki S et al. Gain-of-function of mutated CBL tumour suppressor in myeloid neoplasms. Nature 2009; 460: 904-908.
5. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951.
6. Gelsi-Boyer V, Cervera N, Bertucci F, Trouplin V, Rémy V, Olschwang S et al. Genes expression profiling separates chronic myelomonocytic leukaemia in two molecular subtypes. Leukemia 2007; 21: 2359-2362.
7. Gelsi-Boyer V, Trouplin V, Adéläde J, Aceto N, Remy V, Pinson S et al. Genome profiling of chronic myelomonocytic leukemia:frequent alterations of RAS and RUNX1 genes. BMC Cancer 2008; 8: 299-314.
8. Ohtake F, Baba A, Takada I, Okada M, Iwasaki K, Miki H et al. Dioxin receptor is a ligand-dependent E3 ubiquitin ligase. Nature 2007; 444: 562-566.
9. Take H, Watanabe S, Takeda K, Yu ZX, Iwata N, Kajigaya S. Cloning and characterization of a novel adaptor protein, CIN85, that interacts with c-Cbl. Biochem Biophys Res Commun 2000; 268: 321-328.
10. Soubeyran P, Kowanetz K, Szymkiewicz I, Langdon WY, Dikic I. Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors. Nature 2002; 416: 183-187.
11. Bezsonova I, Bruce MC, Wiesner S, Lin H, Rotin D, Forman-Cay JD. Interactions between the three CIN85 SH3 domains and ubiquitin: implications for CIN85 ubiquitination. Biochemistry 2008; 47: 8937-8949.
12. Havrylov S, Rzheptskyy Y, Malinowska A, Drobot L, Redowicz MJ. Proteins recruited by the SH3 domains of Ruk/CIN85 adaptor identified by LC-MS/MS. Protein Sci 2009; 7: 21.
13. Aissouni Y, Zapart G, Iovanna JL, Dikic I, Soubeyran P. CIN85 regulates the ability of MEKK4 to activate the p38 MAP kinase pathway. Biochem Biophys Res Comm 2005; 338: 808-814.
14. Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009; 41: 838-842.